Kim Byung-Jang – CEO, Mega Medical – South Korea
The CEO of Mega Medical, a Korean medical equipment manufacturer specialized in the ENT area, discusses his firm’s recent expansion into the anti-obesity segment, their strategy for building a global…
Since its establishment in 1995, Mega medical Co., Ltd. has localized medical equipment for ear-note-and throat (ENT), and currently been ranked No. 1 in domestic market share. This company will make every effort not only to maintain No. 1 market share in domestic market but also to take the first position in overseas markets.
1997 Specialized ENT unit launch
1999 Patent acquisition for wall-type nebulizer
2005 Cell-Q, a new obesity treatment product development
2006 Wireless visual system is selected as (wireless visual system) the world best quality product
2007 Digital wireless visual system development
2008 Obesity treatment device solution, Nato irrigation development
2009 HD visual system Development
2010 technical development for ENT Microscope development
2011 LIPO carbon therapy development
2013 Obesity treatment complex device development
Through consistent overseas market development since the establishment, Mega medical Co., Ltd. have exported out products over 40 countries including Europe, Asia, China, and Middle-East, and worked for global network construction.
Contact Details
Domestic inquiries
domestic@megamedical.co.kr
Tel. 1588-4493 (02-3662-4493)
Fax. 02-3661-0120
For overseas clients
Inquiry about products and warranty
webmaster@megamedical.co.kr
Tel. +82-2-3662-4493
Fax. +82-2-3661-0120
Address
#2504, 2505, A Bldg, Woolim blue 9 Business Center, 583, Yangcheon-ro, Gangseo-gu, Seoul (ZIP 157-779)
The CEO of Mega Medical, a Korean medical equipment manufacturer specialized in the ENT area, discusses his firm’s recent expansion into the anti-obesity segment, their strategy for building a global…
Korea, already one of the world’s top clinical research destinations, is looking to boost the efficiency of its clinical trial processes even further by launching K-CThub, a one-stop digital platform…
A wave of blockbuster biologics is set to lose patent protection, creating a major inflection point for the biosimilars market in 2025 and beyond. While Europe remains the global leader…
A roundup of the biggest pharma stories coming out of APAC, including Eisai’s deal with biotech SEED Therapeutics and share drop after Alzheimer’s rejection in the EU; Mayne Pharma’s lawsuit…
A roundup of some of the biggest stories from South Korean healthcare and pharma, including the government’s continuing standoff with doctors over medical reform plans; Merck’s plans for a new…
Despite its ageing population and growing need for healthcare, South Korea had just 2.6 doctors per 1,000 inhabitants in 2022, one of the lowest numbers among developed nations. To deal…
The latest pharma and healthcare news from APAC, including Celltrion’s plans to sell its Takeda portfolio to CBC; reforms to the South Korean national insurance system that may lead to…
Global medtech giant Medtronic is hoping that its latest acquisition – EOFlow, a South Korean wearable insulin patch maker – will enhance its competitiveness in the global diabetes market. …
A roundup of some of the most important recent stories from the burgeoning South Korean pharma and biotech industry, including a government plan to expand collaboration with the global innovation…
As big pharma continues to sharpen its focus on R&D by outsourcing other elements of the supply chain, including manufacturing, CDMOs have thrived. Samsung Biologics, one of the world’s top…
After launching the first Korean COVID-19 vaccine, SKYCovione, SK Bioscience is preparing for its next big milestone, a US subsidiary, with the appointment of two new executives who are already…
SK Bioscience’s announcement that the first batch of its domestically developed COVID vaccine has been shipped may mark a significant milestone in South Korea’s journey towards greater vaccine self-sufficiency. …
ExoCoBio’s CEO, Byong Seung Cho, went from biotech venture capital to setting up ExoCoBio, a company whose core technology is based on adipose stem-cell derived exosomes for regenerative medicine and…
See our Cookie Privacy Policy Here
